A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

• Status: Completed
• Trial end date: 2016-04-07
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)
• Treatments: Calcitriol; Darbepoetin alfa; Epoetin Alfa; Ergocalciferols

Criteria

Inclusion Criteria: A subject will only be included if all the following entry criteria are met:

• Patients ≥ 18 years of age

• Stage 5 chronic kidney disease (CKD) patients receiving hemodialysis and with moderate to severe secondary hyperparathyroidism (SHPT)

• Patients with anemia due to renal insufficiency but who are iron replete:; Transferrin saturation (TSAT) > 20% and Ferritin levels > 200 ng/mL and requiring treatment with erythropoietin (EPO)

• Patients with vitamin B levels > lower limit of normal (LLN) and folic acid levels > LLN

• Patients treated only with intravenous calcitriol for at least 6 months

• Patients with serum intact parathyroid hormone (iPTH) level > 500 pg/mL

• Patients with calcium phosphate product (Ca × PO4) < 65 mg²/dL²

• Patients willing to sign "written informed consents" before participating in any the study related activity.

• Patients with phosphorus levels < 6.5 mg/dL and calcium levels < 11.2 mg/dL

Exclusion Criteria:

A subject will be excluded from the study if he/she meets any of the following criteria:

• Patients who have known hypersensitivity and/or toxicity to vitamin D metabolites and/or to paricalcitol and/or to other product ingredients.

• Patients who have participated in a clinical study within the last month.

• Patients whose previous concomitant medication and laboratory data for 6 months prior to the baseline visit are not available.

• Patients with known contraindication to selective Vitamin D receptor activators (VDRAs) according to the Summary of Product Characteristics (SmPC).

• Pregnancy, breast-feeding or planning a pregnancy within next 6 months after enrollment. Sexually active female patients not accepting appropriate contraceptive methods during the course of the study will also be excluded.

• Hypertensive and diabetic patients who are not on an optimal and steady medication regimen for more than 30 days.

• Patients with microcytic (mean corpuscular volume [MCV] < 80 fL) and macrocytic (MCV > 100 fL) anemia at screening that may be caused by diseases such as for microcytic anemias - Iron Deficiency, Thalassemias, Anemia of Chronic Disease, Copper Deficiency, Zinc poisoning, Sideroblastic Anemia, macrocytic anemias -ethanol abuse, myelodysplastic syndromes, acute myeloid leukemias, reticulocytosis, drug induced anemia, liver disease.